Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Short Interest Up 5.3% in October

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) was the recipient of a significant increase in short interest during the month of October. As of October 15th, there was short interest totalling 4,610,000 shares, an increase of 5.3% from the September 30th total of 4,380,000 shares. Based on an average daily trading volume, of 459,900 shares, the short-interest ratio is currently 10.0 days. Currently, 12.3% of the shares of the company are sold short.

Institutional Trading of Checkpoint Therapeutics

A number of institutional investors have recently bought and sold shares of the company. Gladstone Institutional Advisory LLC grew its position in Checkpoint Therapeutics by 141.4% during the 3rd quarter. Gladstone Institutional Advisory LLC now owns 35,000 shares of the company’s stock worth $78,000 after acquiring an additional 20,500 shares during the last quarter. Wealth Enhancement Advisory Services LLC lifted its position in Checkpoint Therapeutics by 160.0% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 130,000 shares of the company’s stock worth $291,000 after acquiring an additional 80,000 shares during the last quarter. Magnus Financial Group LLC raised its position in shares of Checkpoint Therapeutics by 12.9% in the third quarter. Magnus Financial Group LLC now owns 35,000 shares of the company’s stock valued at $78,000 after buying an additional 4,000 shares in the last quarter. PVG Asset Management Corp bought a new position in Checkpoint Therapeutics in the second quarter valued at approximately $295,000. Finally, B. Riley Wealth Advisors Inc. increased its stake in Checkpoint Therapeutics by 366.3% in the second quarter. B. Riley Wealth Advisors Inc. now owns 229,200 shares of the company’s stock valued at $493,000 after acquiring an additional 180,050 shares during the last quarter. Institutional investors and hedge funds own 22.00% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of Checkpoint Therapeutics in a research note on Monday, September 16th.

Checkpoint Therapeutics Trading Up 2.0 %

Checkpoint Therapeutics stock opened at $3.51 on Friday. The firm has a market capitalization of $158.01 million, a P/E ratio of -1.85 and a beta of 1.30. The stock has a fifty day moving average price of $2.55 and a 200 day moving average price of $2.19. Checkpoint Therapeutics has a 52 week low of $1.36 and a 52 week high of $3.97.

Checkpoint Therapeutics (NASDAQ:CKPT) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.11. The company had revenue of $0.04 million for the quarter. As a group, equities analysts predict that Checkpoint Therapeutics will post -0.81 EPS for the current year.

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.